This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Examining Kodiak Sciences Bi-Specific Clinical Pipeline for Non-Infectious Uveitis and Geographic Atrophy

Ticker(s): KOD, ALPMF, APLS, ABBV

Who's the expert?

Institution: Rush University & Illinois Retina Associates

  • Assistant Professor of Ophthalmology at Rush University Medical Center & co-investigator on several clinical trials.
  • Manages 20 patints a week with wAMD.
  • Research interests include assessing the color performance of the NGENUITY 3D visualization system and meta-analyses of cytokines in various retinal diseases; clinical focus on the medical and surgical treatment of diseases affecting the retina, vitreous and macula.

Interview Questions
Q1.

Roughly how many patients with GA and Non-Infectious Uveitis do you currently manage?

Added By: ben_admin
Q2.

Do you have an opinion on a Bi-Specific approach targeting both Complement Activation and Cytokines in treating GA and NIU?

Added By: ben_admin
Q3.

What is the standard of care for GA and NIU?

Added By: ben_admin
Q4.

What is your high level opinion on the data to date on KSI-102?

Added By: ben_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.